does not block viral entry into CD4 + T cells and has weak anti-HIV-1 activity in vitro 8, 18, 19 . We have recently shown that signaling through Passive transfer of a number of broadly neutralizing antibodies (bNAbs) targeting HIV-1 envelope (Env) has been shown to protect rhesus macaques against a single high-dose inoculation with simian-human immunodeficiency virus (SHIV) [23] [24] [25] [26] and this strategy is currently being evaluated to prevent HIV-1 acquisition in humans 27 . In particular, VRC01, a bNAb against the CD4 binding site (CD4bs) on the HIV envelope 28, 29 , is the first bNAb to be investigated clinically for the prevention of HIV infection in adult men and women (AMP trial; NCT02716675 and NCT02568215). Moreover, VRC01 is being tested for safety in HIV-exposed infants (NCT02256631) as a potential agent to prevent mother-to-child transmission (MTCT) of HIV-1. In preclinical studies, VRC01 protected monkeys against single high-dose vaginal and rectal SHIV challenge 26 and its protective activity against repeated low-dose rectal challenges decreases after several weekly challenges 30 . In this regard, bNAb protection against repeated rectal challenges was shown to be dependent on the potency and half-life of bNAbs 30 . A mutation in the Fc domain of the antibody, which was shown to increase VRC01 half-life in both plasma and tissues, increased 31 and prolonged 30 its protective activity. Several other strategies to improve the pharmacokinetics and function of bNAbs 27 as well as the use of combinations of bNAbs or bi-and trispecific antibody-based molecules [32] [33] [34] are being tested with the ultimate goal of generating new prevention and therapeutic options against HIV-1 infection.
In the present study, we investigated the combination of VRC01 . In order to study the VRC01-Rh-α 4 β 7 combination in a setting of suboptimal VRC01 protection we employed an inoculum 100 fold higher and half the dose of VRC01 (10mg/kg) that resulted in delayed SHIV AD8-EO acquisition for a median of 8 weeks in a repeated rectal low-dose challenge model
30
. A VRC01-alone group was used to monitor baseline VRC01 protection.
A total of 27 animals were infused with VRC01 (10mg/kg) and Rh-α 4 β 7 (25mg/kg; n=9)
or with 10mg/kg of VRC01-alone (n=9) or with control human and rhesus IgGs (n=9), 3 days before weekly vaginal challenges with a high-dose inoculum of SHIV AD8-EO (1000TCID 50 ) until all animals became infected ( Fig 1A) . Rh-α 4 β 7 infusions were repeated every 3 weeks for a total of 6 infusions. The peak concentrations of VRC01 on the day of the first challenge in the VRC01-only group and in the VRC01-Rh-α 4 β 7 group were 98.31 ± 25.83μg/ml and 97.66 ± 55.29 μg/ml (mean±SD), respectively ( Fig 1B) . Of note, for reasons that may be attributed to problems during the infusion, 2 macaques in the VRC01-Rh-α 4 β 7 group had peak concentrations of VRC01 at the time of the first challenge about 10 fold lower than the mean and below the protective concentration against SHIV SF162P3 high-dose challenge 26, 37 . (KT57: 19.145 μg/ml and GH63:
3.350 μg/ml; respectively green and orange in Fig 1B) . Thus, these 2 animals were excluded from the SHIV acquisition analysis. Consistent with previous studies, antibodies against VRC01 (ADA) developed around week 3 after infusion in all VRC01-treated animals and levels were similar in both treatment groups ( Fig S1) . The peak concentration of Rh-α 4 β 7 in the VRC01-Rh-α 4 β 7 group at the time of the first challenge was 112±37 μg/ml (mean±SD; Fig 1C) . One animal with peak concentrations 10 times higher than the average of the other animals was excluded from the calculation of the average. None of the animals had plasma Rh-α 4 β 7 concentrations below the expected range and all 9 animals were included in the analysis of the impact of Rh-α 4 β 7 on acute and early infection parameters. As shown in Fig 1D , all 9 animals in the control group became viremic after 1 to 5 challenges (median of 2 weekly exposures required for infection).
Suboptimal dosing of VRC01 resulted, as expected, in a non-significant delay in SHIV acquisition (Log-rank p=0.074). Nonetheless, the cumulative number of challenges to infect in the VRC01 group was significantly higher than in the control group (Fisher exact test: p=0.02). In the VRC01-Rh-α 4 β 7 combination treatment, it was possible to detect a significant delay in SHIV acquisition (Log-rank p=0.016; Fig 1E) and the difference with the control group in cumulative number of challenges to infect was highly significant (Fisher exact-test: p<0.001). The median number of challenges needed to infect the two treatment groups was similar (n=4) and the VRC01-Rh-α 4 β 7 combination did not significantly delay acquisition compared to VRC01 alone (Log-rank p=0.6). Peak plasma viral load (VL) did not significantly differ between the treatment groups and when comparing the treatment groups with the control group ( Fig 1F and Fig S2) . Setpoint VL was ~1 Log 10 lower in the VRC01-Rh-α 4 β 7 group compared with the other 2 groups ( Fig 1F) . However, the difference did not reach statistical significance (p=0.072 at week 18 p.i. , peripheral CD4 + T cells were protected and CD4 counts were significantly higher in the VRC01-Rh-α 4 β 7 when compared with the other 2 groups (treatment adjusted for time; 2-way Anova p=0.005; Fig 1G) .
Although gut SIV DNA loads were slightly higher in both treatment groups compared with controls at week 3-4 p.i. (2-3 weeks after 1 st virus detection in plasma), by week 20 p.i., VRC01-Rh-α 4 β 7 treated animals had more than 10-fold lower amounts of cellassociated SIV DNA in the gastrointestinal (GI) tract compared to the controls (Fig 2A) .
SIV RNA loads in the GI tract of the VRC01-Rh-α 4 β 7 treated animals were also 100 times lower, on average, than in the control group during the post-acute phase (week 7-8 p.i.; Fig 2B) . However, by week 20 p.i. several animals in the control group had undetectable SIV-RNA levels in the GI tract and the difference with the VRC01-Rh-α 4 β 7 lost its significance. Interestingly, no significant differences in SIV loads were found by directly comparing the VRC01-Rh-α 4 β 7 combination group and the VRC01-alone group and the SIV loads in the VRC01-only group often averaged between the other 2 groups.
Vaginal SIV DNA and RNA loads did not differ in the acute nor in the early chronic phase of the infection among the treatment groups ( Fig S3) . Finally, although the SIV-DNA loads at necropsy (around 20 weeks p.i.) were on average slightly lower in the jejunum and iliac lymph nodes of the VRC01-Rh-α 4 β 7 group compared with the other 2 groups, the differences were not significant (Fig S4) . No differences were detected in other tissues and lymph nodes at necropsy (Fig S4) . Fig 3A-B) . For these subsets, the difference did not reach significance when compared with the VRC01-only group. However, the frequency of IL-17-producing NKG2A + NK cells in blood was significantly lower in the VRC01-Rh-α 4 β 7 group compared with the VRC01-only group (Fig 3A) . In contrast, in the chronic phase, the frequency of IFNγ-producing CD4 -T cells was higher in the VRC01-Rh-α 4 β 7 group compared with the control group in the small intestine ( Fig 3C) . No significant differences in IFNγ-producing cells were noted in blood or upon direct comparison of the VRC01-only group with the VRC01-Rh-α 4 β 7 group nor between the VRC01-only group and the control. No significant differences in IL-17, IL-2, TNFα and IL21-producing cells were noted in these tissues in the chronic phase of infection.
VRC01-
Interestingly, when we investigated how the treatments had impacted immune cells in the lymph nodes at necropsy, we found that in the VRC01-only group had a lower frequency of CD25 + T cells (both CD4 + and CD4 -, Fig 4) compared with the control group. Rh-α 4 β 7 in the VRC01-Rh-α 4 β 7 may have interfered with this decrease since the difference was not significant between the VRC01-Rh-α 4 β 7 group and the controls.
Moreover, we found that the VRC01-treated animals had lower frequencies of CXCR3
CCR6 double positive CD4 -and CD4 + T cells compared with both the VRC01-Rh-α 4 β 7 and the control groups (Fig 4A and B) . Finally, the VRC01-only treated animals had lower CXCR5 + CD4 + follicular T cells in the lymph nodes compared with the controls (Fig 4A) . Fig S6) . T cell responses in the VRC01 group were more similar to the control group, but the difference between the VRC01-only and VRC01-Rh-α 4 β 7 groups reached statistical significance only for TNFα and IL22-secreating CD4 + T cells (Fig S6A) . The responses to gag peptides were generally lower than those to the envelope peptides at this stage of infection in all groups and differences between groups could not be determined.
Since the sequence of the consensus B envelope differs substantially from the sequence of the SHIV AD8-EO envelope in the V1V2 region ( Fig S7) and a specific response against the V2-loop was found in the Rh-α 4 , we synthetized seven 20-mer, 14aa overlapping peptides spanning the V1V2 region that differs between the SHIV AD8-EO and the consensus B envelope and used them to probe T cells and antibody responses. Interestingly, the VRC01-Rh-α 4 β 7 macaques had higher frequencies of IFNγ-producing CD4 + T cells in response to the V1V2 peptide pool than both the VRC01 and control groups ( Fig 5A) . In contrast, TNFα-producing CD4 + T cells and IFN-γ-producing CD8 + T cells were higher in both treatment groups compared with the control group (Fig 5A-B) . A higher IL-17 response in the CD8 + T cell subset was also noted in the VRC01-Rh-α 4 β 7 group compared to the controls ( Fig 5B) . Finally, a higher frequency of TNF-α-CD8 + T cells was present in the VRC01-Rh-α 4 β 7 group compared with the VRC01-only group. In summary, higher T cell responses were detected against the V1V2 loop in the VRC01-Rh-α 4 β 7 group particularly compared to control animals.
Total anti-HIV envelope antibodies were tested against the HIV-Bal envelope protein and no differences were noted between the groups. Moreover, a peptide scan against consensus B envelope peptides (with the 8 peptides corresponding to the V1V2 loop replaced by the 7 SHIV-AD8-specific peptides that we had synthetized) was carried out on sera from 4 animals in each group with the highest antibody responses. No clear differences in the response to specific regions of the envelope were noted between the groups ( Fig S8) .
DISCUSSION
bNAbs are being tested in the clinic for the prevention and therapy of HIV infection.
VRC01 is the first to reach efficacy testing and other bNAbs will soon follow 39, 40 .
However, it is clear that individual bNAbs cannot be used alone as a single intervention.
Combinations of more bNAbs or bi-or tri-specific molecules need to be employed to achieve better and more durable protection from HIV acquisition 32, [41] [42] [43] . Moreover, recent data suggest that bNAbs treatment may impact immune responses to infection [44] [45] [46] . This feature represents a potential new therapeutic approach toward an HIV-1 cure. 
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MATERIALS AND METHODS
Macaques and treatments
A total of 27 adult female Indian rhesus macaques (average weight 8.1Kg, range: 4.5, 13.05 and age 9.5 years, range: 3.9, 18) were socially housed, indoors, in climate acute phase) fresh rectal biopsies and blood were used for cell isolation as described below. Subsequently, blood was collected every two weeks throughout the study. Rectal and vaginal samples were also collected at 7-8 weeks post infection (post-acute phase).
At necropsy, blood, lymph nodes, gut, brain, vaginal and cervical tissues were harvested and used for cell isolation. 
Measurement of plasma levels of VRC01 and
SHIV AD8-EO stock generation and titration
The full-length proviral plasmid pSHIVAD8-EO was a gift from Dr. Malcom Martin. Virus stocks were prepared by transfecting 293T cells with 5μg of the pSHIV AD8-EO molecular clone using Lipofectamine 2000 (Invitrogen). Culture supernatant was collected 60 hours later, clarified by centrifugation (300g 10 minutes, 4°C) and used to infect CD8-depleted, PHA-activated rhesus macaque PBMC. Cells were incubated overnight in 293T supernatants, washed and resuspended in RPMI 10% FBS medium for 10 days.
Supernatants from parallel cultures were pooled on day 7, clarified by centrifugation (10,000g, 15minutes, 4°C), aliquoted, and stored at -80°C. The resulting stock was titrated in PHA-activated rhesus macaque PBMC.
SIV viral loads
Macaque infection was confirmed by SIVgag nested PCR on PBMC as described [49] .
Plasma samples were obtained from EDTA-treated whole blood and used for the 
Statistics
To analyze the differences in SHIV acquisition, the survival curves generated with time to first viral detection in plasma from each treatment group were compared to each other directly and each with the curve from the control group using the Log-rank (Mantel-Cox) test. The cumulative number of challenges needed to infect in each group was also compared to the cumulative number in each other group by Fisher exact test.
Viral loads and CD4 counts were compared by two-way ANOVA for repeated measures.
To address whether either treatment had a significantly different effect on infection and immunological parameters than the control group, data was analyzed using Kruskal- 
